DNA methylation is very important for normal development and has been involved in many pathologies including cancer. Our knowledge of the distribution of the DNA methylation genome, how it changes during cellular differentiation and how it relates to histone methylation and other chromatine modifications to mammals remain limited. Here we report generations and analysis of dna methylation profiles of genome scale at nucleotide resolution in mammalian cells.
Using high-throughput representation Reduced sequencing bisulfite and single molecular-based sequencing, we produce DNA methylation maps that cover most CPG islands, and sampling representatives of non-coding elements that are preserved, transposon, and other genome features, for mouse embryonic stem cells , embryonic -Sem – primary nerve cells, and eight other primary networks. Some of the main findings arise from the data.
First, the DNA methylation pattern is more correlated with the pattern of histone methylation than with the context of the underlying genome sequence. Second, CPG methylation is a dynamic epigenetic sign that undergoes extensive change during cellular differentiation, especially in regulatory areas outside the core promoter.
Third, the analysis of cells originating from embryonic and primary reveals that the ‘weak’ CPG Islands associated with a series of genes regulated specifically undergoing hypermethylation which deviate during the proliferation that is expanded in vitro, in a pattern reminded at some Main tumor. More generally, the results establish sequential representation as a strong technology for cell population epigenetic profiles relevant to biological development, cancer and regenerative treatment.
Histone H3K27AC separates actively from the enhancer that is ready and predict the development state.
The development program is controlled by transcription factors and chromatin regulators, which maintain certain gene expression programs through genome epigenetic modifications. Events of this regulation in enhancing contributing to the specific gene expression program that determines the state of cells and potential differentiation into new cell types.
Although the enhancer elements are known to be related to certain histon modifications and transcription factors, this modification relationship in gene expression and the state of development has not been clearly defined. Here we interrogate the epigenetic landscape of elements in embryonic stem cells and some adult networks in the mouse. We found that Histone H3K27AC distinguishes the active enhancer of an inactive / ready enhancing element that contains H3K4ME1.
It shows that the number of enhancers used actively lower than previously anticipated. Furthermore, Network Enhancers are ready to provide instructions for unrealized development programs. Finally, we showed that the released enhancer during nuclear reprogramming.
Circular RNA is a large class of animal ras with potential regulations.
Circular RNA (CIRCRNAS) in animals is a class of UGI RNA with unknown functions. To explore CIRCRNAS systematically, we sort and computed to analyze human RNA, mouse, and nematodes. We detect thousands of stable CIRCRNAS expressed well, often showing specific expressions of tissue / development-specific. Order analysis shows important regulatory functions for CIRCRNAS.
We found that a human Circrna, AntiSense against protein transcripts 1 related to ceregelar degeneration (CDR1A), was very bound by the Effector Complex Michorna (MIRNA) and Harbors 63 preserving the binding site for the ancient Mirna MIRNA. Further analysis shows that CDR1as serves to bind MIR-7 on network neurons. CDR1AS human expression in zebra that has disrupted the development of the midbrain, is similar to knocking down MIR-7, indicating that the CDR1A is a mirna antagonist with a capacity that binds Mirna ten times higher than other known transcripts. Together, our data provides evidence that CIRCRNAS forms a large class post-transricted regulator. Many forms of Circrnas with the splicing of the head-to-tail exon, indicating the potential of previous unknown regulations from the sequence of coding.
Landak signal inhibition increases chemotherapy delivery in the pancreatic cancer mouse model.
Adenocarcinoma Pancreatic Duct (PDA) is one of the most deadly human cancers partly because it is not sensitive to many chemotherapy drugs. Studying the fire-resistant PDA mouse model against gemcitabine drugs used clinically, we find that tumors in this model are less perfusion and poor vascularization, properties that are shared with human pda.
 DAB Chromogen Kit |
|||
| abx097197-1Kit | Abbexa | 1 Kit | EUR 272 |
|
|||
 DAB Away Kit |
|||
| ACP001 | ScyTek Laboratories | 500 ml | EUR 98 |
-Chlorpheg) (2R,3S)-Chlorpheg |
|||
| B6462-10 | ApexBio | 10 mg | EUR 502 |
-E1R) (2R,3S)-E1R |
|||
| HY-116463A | MedChemExpress | 10mM/1mL | EUR 1663 |
-E1R) (2S,3S)-E1R |
|||
| HY-116463B | MedChemExpress | 5mg | EUR 1175 |
-Tofacitinib) (3S,4R)-Tofacitinib |
|||
| HY-40354B | MedChemExpress | 5mg | EUR 3494 |
-Tofacitinib) (3S,4S)-Tofacitinib |
|||
| HY-40354C | MedChemExpress | 10mM/1mL | EUR 3838 |
-Lateritin) (3S,6R)-Lateritin |
|||
| GL6358-1MG | Glentham Life Sciences | 1 mg | EUR 229 |
 SAM ELISA 3s |
|||
| IK00203s | Arthus | 48 tests | EUR 503 |
|
Description: S-adenosylmethionine ELISA kit for plasma, serum, or tissue/cell homogenate samples, broad range |
|||
-(-)-Glucodistylin) (2S,3S)-(-)-Glucodistylin |
|||
| TBW00642 | ChemNorm | unit | Ask for price |
]-OH) Fmoc-Dab[Fmoc-Dab(Boc)]-OH |
|||
| 5-04727 | CHI Scientific | 5g | Ask for price |
Fmoc-Dab[Fmoc-Dab(Boc)]-OH |
|||
| 5-04728 | CHI Scientific | 25g | Ask for price |
 DAB Chromogen/Substrate Kit |
|||
| ACH500 | ScyTek Laboratories | 500 Slides | EUR 85 |
 Sensitive DAB Stain Kit |
|||
| PW023 | Bio Basic | 5Preps, 5prep | EUR 69.14 |
|
|||
 DAB Tablet |
|||
| D3225-020 | GenDepot | 20TB | EUR 142 |
DAB Tablet |
|||
| D3225-050 | GenDepot | 50TB | EUR 246 |
-3-Aminocyclohexanol) (1S,3S)-3-Aminocyclohexanol |
|||
| 20-abx184840 | Abbexa |
|
|
|
|||
-3-Phenylisoserine) (2R,3S)-3-Phenylisoserine |
|||
| F-3890.0250 | Bachem | 250.0mg | EUR 381 |
|
Description: Sum Formula: C9H11NO3; CAS# [136561-53-0] net |
|||
(2R,3S)-3-Phenylisoserine |
|||
| F-3890.1000 | Bachem | 1.0g | EUR 1070 |
|
Description: Sum Formula: C9H11NO3; CAS# [136561-53-0] net |
|||
-3-Phenylisoserinehydrochloride) (2R,3S)-3-Phenylisoserinehydrochloride |
|||
| TWK02005 | ChemNorm | 20mg | Ask for price |
-3-phenylisoserinemethylester) (2R,3S)-3-phenylisoserinemethylester |
|||
| TRB0102 | ChemNorm | 250mg | Ask for price |
) DAB Chromogenic Substrate Kit (Brown) |
|||
| AR1022 | BosterBio | 1 kit (for 600-900 assays) | EUR 80 |
) DAB Chromogenic Substrate Kit (Blue) |
|||
| AR1025 | BosterBio | 1 kit (for 600-900 assays) | EUR 80 |
 DAB Horseradish Peroxidase Chromogenic Kit |
|||
| 20-abx090660 | Abbexa |
|
|
|
|||
-Fmoc-3-phenylisoserine) (2R,3S)-Fmoc-3-phenylisoserine |
|||
| B-3405.0250 | Bachem | 250.0mg | EUR 345 |
|
Description: Sum Formula: C24H21NO5; CAS# [252206-27-2] |
|||
(2R,3S)-Fmoc-3-phenylisoserine |
|||
| B-3405.1000 | Bachem | 1.0g | EUR 986 |
|
Description: Sum Formula: C24H21NO5; CAS# [252206-27-2] |
|||
-Boc-3-phenylisoserine) (2R,3S)-Boc-3-phenylisoserine |
|||
| A-4530.0250 | Bachem | 250.0mg | EUR 381 |
|
Description: Sum Formula: C14H19NO5; CAS# [145514-62-1] |
|||
(2R,3S)-Boc-3-phenylisoserine |
|||
| A-4530.1000 | Bachem | 1.0g | EUR 1070 |
|
Description: Sum Formula: C14H19NO5; CAS# [145514-62-1] |
|||
-Atorvastatin (sodium salt)) (3S,5S)-Atorvastatin (sodium salt) |
|||
| C4030-1 | ApexBio | 1 mg | EUR 134 |
|
Description: Atorvastatin exists in four optical forms. The (3R, 5R)-atorvastatin enantiomer displays the greatest activity against HMG-CoA reductase. (3S,5S)-Atorvastatin is an enantiomer of atorvastatin with little or no inhibitory activity against HMG-CoA reductase [1]. |
|||
(3S,5S)-Atorvastatin (sodium salt) |
|||
| C4030-10 | ApexBio | 10 mg | EUR 718 |
|
Description: Atorvastatin exists in four optical forms. The (3R, 5R)-atorvastatin enantiomer displays the greatest activity against HMG-CoA reductase. (3S,5S)-Atorvastatin is an enantiomer of atorvastatin with little or no inhibitory activity against HMG-CoA reductase [1]. |
|||
(3S,5S)-Atorvastatin (sodium salt) |
|||
| C4030-5 | ApexBio | 5 mg | EUR 425 |
|
Description: Atorvastatin exists in four optical forms. The (3R, 5R)-atorvastatin enantiomer displays the greatest activity against HMG-CoA reductase. (3S,5S)-Atorvastatin is an enantiomer of atorvastatin with little or no inhibitory activity against HMG-CoA reductase [1]. |
|||
-Boc-3-Phenylisoserine) (2R,3S)-Boc-3-Phenylisoserine |
|||
| TRS0139 | ChemNorm | 20mg | Ask for price |
 H-Dab-OH·HCl |
|||
| 5-04703 | CHI Scientific | 5g | Ask for price |
H-Dab-OH·HCl |
|||
| 5-04704 | CHI Scientific | 25g | Ask for price |
 Boc-Dab-OH |
|||
| 5-04711 | CHI Scientific | 5g | Ask for price |
Boc-Dab-OH |
|||
| 5-04712 | CHI Scientific | 25g | Ask for price |
 Fmoc-Dab-OAll·HCl |
|||
| 5-04720 | CHI Scientific | 5g | Ask for price |
 Fmoc-Dab-OH·HCl |
|||
| 5-04721 | CHI Scientific | 5g | Ask for price |
Fmoc-Dab-OH·HCl |
|||
| 5-04722 | CHI Scientific | 25g | Ask for price |
 Fmoc-Dab-OH |
|||
| 5-04735 | CHI Scientific | 1g | Ask for price |
Fmoc-Dab-OH |
|||
| 5-04736 | CHI Scientific | 5g | Ask for price |
Fmoc-Dab-OH |
|||
| B-2300.0001 | Bachem | 1.0g | EUR 151 |
|
Description: Sum Formula: C19H20N2O4; CAS# [161420-87-7] |
|||
Fmoc-Dab-OH |
|||
| B-2300.0005 | Bachem | 5.0g | EUR 515 |
|
Description: Sum Formula: C19H20N2O4; CAS# [161420-87-7] |
|||
 DAB Chromogen Concentrate |
|||
| D3226-002 | GenDepot | 20ml | EUR 161 |
DAB Chromogen Concentrate |
|||
| D3226-005 | GenDepot | 50ml | EUR 334 |
 DAB Differentiating Solution |
|||
| DDS500 | ScyTek Laboratories | 500 ml | EUR 109 |
Boc-Dab-OH |
|||
| A-3215.0001 | Bachem | 1.0g | EUR 126 |
|
Description: Sum Formula: C9H18N2O4; CAS# [25691-37-6] |
|||
Boc-Dab-OH |
|||
| A-3215.0005 | Bachem | 5.0g | EUR 418 |
|
Description: Sum Formula: C9H18N2O4; CAS# [25691-37-6] |
|||
Boc-Dab-OH |
|||
| A-3215.0025 | Bachem | 25.0g | EUR 1578 |
|
Description: Sum Formula: C9H18N2O4; CAS# [25691-37-6] |
|||
DAB Chromogen Concentrate |
|||
| ACB030 | ScyTek Laboratories | 30 ml | EUR 119 |
DAB Chromogen Concentrate |
|||
| ACB060 | ScyTek Laboratories | 60 ml | EUR 165 |
DAB Chromogen Concentrate |
|||
| ACB125 | ScyTek Laboratories | 125 ml | EUR 245 |
DAB Chromogen Concentrate |
|||
| ACB500 | ScyTek Laboratories | 500 ml | EUR 671 |
DAB Chromogen Concentrate |
|||
| ACB999 | ScyTek Laboratories | 1000 ml | EUR 1159 |
 DAB Substrate Buffer |
|||
| ACC500 | ScyTek Laboratories | 500 ml | EUR 72 |
DAB Substrate Buffer |
|||
| ACC999 | ScyTek Laboratories | 1000 ml | EUR 80 |
 DAB Enhancer Solution |
|||
| ACM030 | ScyTek Laboratories | 30 ml | EUR 71 |
 Z-Dab-OH |
|||
| C-3705.0001 | Bachem | 1.0g | EUR 115 |
|
Description: Sum Formula: C12H16N2O4; CAS# [62234-40-6] |
|||
Z-Dab-OH |
|||
| C-3705.0005 | Bachem | 5.0g | EUR 273 |
|
Description: Sum Formula: C12H16N2O4; CAS# [62234-40-6] |
|||
Z-Dab-OH |
|||
| C-3705.0025 | Bachem | 25.0g | EUR 998 |
|
Description: Sum Formula: C12H16N2O4; CAS# [62234-40-6] |
|||
 DL-Dab.2HCl |
|||
| A6727-100000 | ApexBio | 100 g | EUR 569 |
|
Description: DL-Dab.2HCl |
|||
DL-Dab.2HCl |
|||
| A6727-25000 | ApexBio | 25 g | EUR 309 |
|
Description: DL-Dab.2HCl |
|||
DL-Dab.2HCl |
|||
| A6727-5000 | ApexBio | 5 g | EUR 180 |
|
Description: DL-Dab.2HCl |
|||
 H-Dab-OH |
|||
| F-3050.0001 | Bachem | 1.0g | EUR 115 |
|
Description: Sum Formula: C4H10N2O2; CAS# [1883-09-6] |
|||
H-Dab-OH |
|||
| F-3050.0005 | Bachem | 5.0g | EUR 225 |
|
Description: Sum Formula: C4H10N2O2; CAS# [1883-09-6] |
|||
H-Dab-OH |
|||
| F-3050.0025 | Bachem | 25.0g | EUR 803 |
|
Description: Sum Formula: C4H10N2O2; CAS# [1883-09-6] |
|||
 DAB Chromogen, 4ml |
|||
| NB314D | Innovex | 4 ml | EUR 246 |
 Frit Kit |
|||
| FRIT-KIT | Next Advance | 1each | EUR 124 |
|
Description: Kit to create frits in capillaries. Includes formamide, Kasil-1, Kasil-1624 and a cleaving tool. |
|||
 Column Packing Kit |
|||
| PACK-KIT | Next Advance | 1pack | EUR 1035 |
|
Description: Column packing kit for pressure cells. Includes: HPREG regulator, TBNG10 tubing, CAP-75 capillary, and STRB5X2 stir bar. |
|||
 PCR Mycoplasma Detection Kit |
|||
| M034-Kit | TOKU-E | Kit | EUR 266 |
) DAB Chromogen/Substrate Kit (High Contrast) |
|||
| ACT500 | ScyTek Laboratories | 500 Slides | EUR 157 |
-3-aminocyclohexan-1-ol) (1R,3S)-3-aminocyclohexan-1-ol |
|||
| 20-abx184837 | Abbexa |
|
|
|
|||
-Methyl 3-aminocyclopentanecarboxylate hydrochloride) (1S,3S)-Methyl 3-aminocyclopentanecarboxylate hydrochloride |
|||
| abx186027-1g | Abbexa | 1 g | EUR 2764 |
|
|||
-3-phenylisoserine) N-Benzoyl-(2R,3S)-3-phenylisoserine |
|||
| HY-N2380 | MedChemExpress | 10mg | EUR 108 |
N-Benzoyl-(2R,3S)-3-phenylisoserine |
|||
| TBZ2844 | ChemNorm | 20mg | Ask for price |
 DAB Enhancer for ampliying DAB stains in IHC staining, 60ml |
|||
| NB308 | Innovex | 60 ml | EUR 427 |
 DAB Enhancer for ampliying DAB stains in IHC staining, 30ml |
|||
| NB308-30 | Innovex | 30 ml | EUR 299 |
 Cas9 Protein and T7 gRNA SmartNuclease Synthesis Kit |
|||
| CAS400A-KIT | SBI | 1 kit (10 rxn) | EUR 1110 |
|
|||
-OH) H-Dab(Z)-OH |
|||
| 5-04707 | CHI Scientific | 5g | Ask for price |
H-Dab(Z)-OH |
|||
| 5-04708 | CHI Scientific | 25g | Ask for price |
-OH·DCHA) Boc-Dab(Boc)-OH·DCHA |
|||
| 5-04713 | CHI Scientific | 1g | Ask for price |
Boc-Dab(Boc)-OH·DCHA |
|||
| 5-04714 | CHI Scientific | 5g | Ask for price |
-OH) Boc-Dab(Fmoc)-OH |
|||
| 5-04715 | CHI Scientific | 5g | Ask for price |
Boc-Dab(Fmoc)-OH |
|||
| 5-04716 | CHI Scientific | 25g | Ask for price |
-OH·DCHA) Boc-Dab(Z)-OH·DCHA |
|||
| 5-04717 | CHI Scientific | 5g | Ask for price |
Boc-Dab(Z)-OH·DCHA |
|||
| 5-04718 | CHI Scientific | 25g | Ask for price |
-OH) Fmoc-Dab(Ac)-OH |
|||
| 5-04723 | CHI Scientific | 5g | Ask for price |
Fmoc-Dab(Ac)-OH |
|||
| 5-04724 | CHI Scientific | 25g | Ask for price |
-OH) Fmoc-Dab(Boc)-OH |
|||
| 5-04725 | CHI Scientific | 5g | Ask for price |
Fmoc-Dab(Boc)-OH |
|||
| 5-04726 | CHI Scientific | 25g | Ask for price |
-OH) Fmoc-Dab(Fmoc)-OH |
|||
| 5-04729 | CHI Scientific | 1g | Ask for price |
Fmoc-Dab(Fmoc)-OH |
|||
| 5-04730 | CHI Scientific | 5g | Ask for price |
-OH) Fmoc-Dab(MMt)-OH |
|||
| 5-04731 | CHI Scientific | 5g | Ask for price |
Fmoc-Dab(MMt)-OH |
|||
| 5-04732 | CHI Scientific | 25g | Ask for price |
-OH) Fmoc-Dab(Mtt)-OH |
|||
| 5-04733 | CHI Scientific | 1g | Ask for price |
Fmoc-Dab(Mtt)-OH |
|||
| 5-04734 | CHI Scientific | 5g | Ask for price |
-OH) Fmoc-Dab(Dde)-OH |
|||
| 5-04739 | CHI Scientific | 1g | Ask for price |
Fmoc-Dab(Dde)-OH |
|||
| 5-04740 | CHI Scientific | 5g | Ask for price |
-OH) Fmoc-Dab(ivDde)-OH |
|||
| 5-04741 | CHI Scientific | 1g | Ask for price |
Fmoc-Dab(ivDde)-OH |
|||
| 5-04742 | CHI Scientific | 5g | Ask for price |
-OH) Fmoc-Dab(Z)-OH |
|||
| 5-04743 | CHI Scientific | 1g | Ask for price |
Fmoc-Dab(Z)-OH |
|||
| 5-04744 | CHI Scientific | 5g | Ask for price |
 Boc-D-Dab-OH |
|||
| 5-04745 | CHI Scientific | 1g | Ask for price |
Boc-D-Dab-OH |
|||
| 5-04746 | CHI Scientific | 5g | Ask for price |
 Fmoc-D-Dab-OH |
|||
| 5-04751 | CHI Scientific | 1g | Ask for price |
Fmoc-D-Dab-OH |
|||
| 5-04752 | CHI Scientific | 5g | Ask for price |
-OH) Fmoc-Dab(Aloc)-OH |
|||
| B-2850.0001 | Bachem | 1.0g | EUR 297 |
|
Description: Sum Formula: C23H24N2O6; CAS# [204316-32-5] |
|||
Fmoc-Dab(Aloc)-OH |
|||
| B-2850.0005 | Bachem | 5.0g | EUR 1106 |
|
Description: Sum Formula: C23H24N2O6; CAS# [204316-32-5] |
|||
Fmoc-Dab(Z)-OH |
|||
| B-3250.0001 | Bachem | 1.0g | EUR 261 |
|
Description: Sum Formula: C27H26N2O6; CAS# [252049-08-4] |
|||
Fmoc-Dab(Z)-OH |
|||
| B-3250.0005 | Bachem | 5.0g | EUR 925 |
|
Description: Sum Formula: C27H26N2O6; CAS# [252049-08-4] |
|||
Fmoc-Dab(ivDde)-OH |
|||
| B-4065.0001 | Bachem | 1.0g | EUR 297 |
|
Description: Sum Formula: C32H38N2O6; CAS# [607366-21-2] |
|||
Fmoc-Dab(ivDde)-OH |
|||
| B-4065.0005 | Bachem | 5.0g | EUR 1093 |
|
Description: Sum Formula: C32H38N2O6; CAS# [607366-21-2] |
|||
Fmoc-Dab(Boc)-OH |
|||
| B-1800.0001 | Bachem | 1.0g | EUR 200 |
|
Description: Sum Formula: C24H28N2O6; CAS# [125238-99-5] |
|||
Fmoc-Dab(Boc)-OH |
|||
| B-1800.0005 | Bachem | 5.0g | EUR 683 |
|
Description: Sum Formula: C24H28N2O6; CAS# [125238-99-5] |
|||
Fmoc-Dab(Fmoc)-OH |
|||
| B-2270.0001 | Bachem | 1.0g | EUR 236 |
|
Description: Sum Formula: C34H30N2O6; CAS# [201473-83-8] |
|||
Fmoc-Dab(Fmoc)-OH |
|||
| B-2270.0005 | Bachem | 5.0g | EUR 866 |
|
Description: Sum Formula: C34H30N2O6; CAS# [201473-83-8] |
|||
Fmoc-D-Dab-OH |
|||
| B-2365.0001 | Bachem | 1.0g | EUR 418 |
|
Description: Sum Formula: C19H20N2O4; CAS# [201484-12-0] |
|||
Fmoc-D-Dab-OH |
|||
| B-2365.0005 | Bachem | 5.0g | EUR 1554 |
|
Description: Sum Formula: C19H20N2O4; CAS# [201484-12-0] |
|||
 Enhancing Solution) DAB (Post) Enhancing Solution |
|||
| DES500 | ScyTek Laboratories | 500 ml | EUR 88 |
DAB (Post) Enhancing Solution |
|||
| DES999 | ScyTek Laboratories | 1000 ml | EUR 109 |
-OH) H-Dab(Boc)-OH |
|||
| A-3305.0001 | Bachem | 1.0g | EUR 200 |
|
Description: Sum Formula: C9H18N2O4; CAS# [10270-94-7] |
|||
H-Dab(Boc)-OH |
|||
| A-3305.0005 | Bachem | 5.0g | EUR 696 |
|
Description: Sum Formula: C9H18N2O4; CAS# [10270-94-7] |
|||
Boc-Dab(Fmoc)-OH |
|||
| A-3520.0001 | Bachem | 1.0g | EUR 225 |
|
Description: Sum Formula: C24H28N2O6; CAS# [117106-21-5] |
|||
Boc-Dab(Fmoc)-OH |
|||
| A-3520.0005 | Bachem | 5.0g | EUR 780 |
|
Description: Sum Formula: C24H28N2O6; CAS# [117106-21-5] |
|||
-OH) Boc-Dab(Aloc)-OH |
|||
| A-4125.0001 | Bachem | 1.0g | EUR 309 |
|
Description: Sum Formula: C13H22N2O6; CAS# [171820-73-8] |
|||
Boc-Dab(Aloc)-OH |
|||
| A-4125.0005 | Bachem | 5.0g | EUR 1143 |
|
Description: Sum Formula: C13H22N2O6; CAS# [171820-73-8] |
|||
Boc-D-Dab-OH |
|||
| A-4215.0001 | Bachem | 1.0g | EUR 418 |
|
Description: Sum Formula: C9H18N2O4; CAS# [80445-78-9] |
|||
Boc-D-Dab-OH |
|||
| A-4215.0005 | Bachem | 5.0g | EUR 1554 |
|
Description: Sum Formula: C9H18N2O4; CAS# [80445-78-9] |
|||
 Boc-Dab-OtBu · HCl |
|||
| A-4415.0001 | Bachem | 1.0g | EUR 309 |
|
Description: Sum Formula: C13H26N2O4·HCl; CAS# [190447-69-9] net |
|||
Boc-Dab-OtBu · HCl |
|||
| A-4415.0005 | Bachem | 5.0g | EUR 1143 |
|
Description: Sum Formula: C13H26N2O4·HCl; CAS# [190447-69-9] net |
|||
-Oh) Fmoc-Dab(Fmoc)-Oh |
|||
| abx188721-250g | Abbexa | 250 g | EUR 1720 |
|
|||
) DAB Substrate (High Contrast) |
|||
| ACU250 | ScyTek Laboratories | 250 ml | EUR 85 |
DAB Substrate (High Contrast) |
|||
| ACU500 | ScyTek Laboratories | 500 ml | EUR 98 |
DAB Substrate (High Contrast) |
|||
| ACU999 | ScyTek Laboratories | 1000 ml | EUR 119 |
-OH) Z-Dab(Z)-OH |
|||
| C-3690.0001 | Bachem | 1.0g | EUR 200 |
|
Description: Sum Formula: C20H22N2O6; CAS# [55478-23-4] |
|||
Z-Dab(Z)-OH |
|||
| C-3690.0005 | Bachem | 5.0g | EUR 696 |
|
Description: Sum Formula: C20H22N2O6; CAS# [55478-23-4] |
|||
 Z-D-Dab-OH |
|||
| C-3770.0001 | Bachem | 1.0g | EUR 225 |
|
Description: Sum Formula: C12H16N2O4; CAS# [70882-66-5] |
|||
Z-D-Dab-OH |
|||
| C-3770.0005 | Bachem | 5.0g | EUR 792 |
|
Description: Sum Formula: C12H16N2O4; CAS# [70882-66-5] |
|||
) 10-DAB (10-Deacetylbaccatin) |
|||
| A4395-25 | ApexBio | 25 mg | EUR 514 |
|
Description: 10-DAB (also known as 10-Deacetylbaccatin) is an intermediate used for the preparation of taxol, an anti-leukemic and tumor-inhibiting agent isolated from the inner bark of the Pacific yew tree Taxus brevifolia as well as other species of the genus Taxus. |
|||
10-DAB (10-Deacetylbaccatin) |
|||
| A4395-5 | ApexBio | 5 mg | EUR 166 |
|
Description: 10-DAB (also known as 10-Deacetylbaccatin) is an intermediate used for the preparation of taxol, an anti-leukemic and tumor-inhibiting agent isolated from the inner bark of the Pacific yew tree Taxus brevifolia as well as other species of the genus Taxus. |
|||
10-DAB (10-Deacetylbaccatin) |
|||
| A4395-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 293 |
|
Description: 10-DAB (also known as 10-Deacetylbaccatin) is an intermediate used for the preparation of taxol, an anti-leukemic and tumor-inhibiting agent isolated from the inner bark of the Pacific yew tree Taxus brevifolia as well as other species of the genus Taxus. |
|||
10-DAB (10-Deacetylbaccatin) |
|||
| A4395-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: 10-DAB (also known as 10-Deacetylbaccatin) is an intermediate used for the preparation of taxol, an anti-leukemic and tumor-inhibiting agent isolated from the inner bark of the Pacific yew tree Taxus brevifolia as well as other species of the genus Taxus. |
|||
-OH) Ac-Dab(Boc)-OH |
|||
| F-1020.0250 | Bachem | 250.0mg | EUR 236 |
|
Description: Sum Formula: C11H20N2O5; CAS# [201351-32-8] |
|||
Ac-Dab(Boc)-OH |
|||
| F-1020.1000 | Bachem | 1.0g | EUR 660 |
|
Description: Sum Formula: C11H20N2O5; CAS# [201351-32-8] |
|||
 H-D-Dab-OH |
|||
| F-3055.0001 | Bachem | 1.0g | EUR 225 |
|
Description: Sum Formula: C4H10N2O2; CAS# [26908-94-1] net |
|||
H-D-Dab-OH |
|||
| F-3055.0005 | Bachem | 5.0g | EUR 792 |
|
Description: Sum Formula: C4H10N2O2; CAS# [26908-94-1] net |
|||
 DAB Substrate buffer, 70ml |
|||
| NB314SB | Innovex | 70 ml | EUR 276 |
 CMV-hspCas9-T2A-Puro SmartNuclease Lentivector Plasmid + LentiStarter Packaging Kit |
|||
| CASLV100PA-KIT | SBI | 1 Kit | EUR 1132 |
|
|||
 CMV-hspCas9-EF1-GFP SmartNuclease Lentivector Plasmid + LentiStarter Packaging Kit |
|||
| CASLV105PA-KIT | SBI | 1 Kit | EUR 1132 |
|
|||
 MSCV-hspCas9-T2A-Puro SmartNuclease Lentivector Plasmid + LentiStarter Packaging Kit |
|||
| CASLV120PA-KIT | SBI | 1 Kit | EUR 1132 |
|
|||
 MSCV-hspCas9-EF1-GFP SmartNuclease Lentivector Plasmid + LentiStarter Packaging Kit |
|||
| CASLV125PA-KIT | SBI | 1 Kit | EUR 1132 |
|
|||
 Multiplex gRNA Kit + EF1-T7-hspCas9-H1-gRNA linearized SmartNuclease vector |
|||
| CAS700A-KIT | SBI | 10 rxn | EUR 1132 |
|
|||
 Multiplex gRNA Kit + CAG-T7-hspCas9-H1-gRNA linearized SmartNuclease vector |
|||
| CAS720A-KIT | SBI | 10 rxn | EUR 1132 |
|
|||
 Multiplex gRNA Kit + CMV-T7-hspCas9-H1-gRNA linearized SmartNuclease vector |
|||
| CAS740A-KIT | SBI | 10 rxn | EUR 1132 |
|
|||
) T7 gRNA SmartNuclease Synthesis Kit (includes CAS510A-1 & T7 IVT synthesis reagents) |
|||
| CAS510A-KIT | SBI | 1 Kit | EUR 805 |
|
|||
We test whether the shipment and efficacy of gemcitabine in mice can be increased by the Coadministration IPI-926, drugs that spend stromal tissue related to tumors by inhibiting the cellular ledge signal path. Combination therapy produces an increase in transient in intratumoral vascular density and intratumoral concentration of gemcitabine, which leads to temporary disease stabilization. Thus, the administration of an inefficient drug may be an important contributor to kimoresistance in pancreatic cancer.